864 results on '"Thieblemont, C."'
Search Results
2. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
3. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†
4. HSD10 The Hospital Care Pathway of Patients Treated By Axi-Cel and Tisa-Cel between 2018 and 2021 in France: A National Study Based on the Comprehensive Inpatient Stays Database
5. Observance des méthodes contraceptives pre-IVG et analyse des changements comportementaux post-IVG
6. Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective
7. Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX
8. IBRUTINIB PLUS BR OR R‐CHOP IN PREVIOUSLY TREATED PATIENTS WITH FOLLICULAR OR MARGINAL ZONE LYMPHOMA: THE PHASE 3 SELENE STUDY
9. Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA
10. RITUXIMAB AND IBRUTINIB COMBINATION IS SAFE AND EFFECTIVE IN UNTREATED SPLENIC AND NODAL MARGINAL ZONE LYMPHOMAS: PLANNED SUBSET ANALYSIS OF THE IELSG47/MALIBU PHASE II STUDY
11. RISK STRATIFICATION OF DLBCL WITH MVED2 SCORE USING INTEGRATIVE HOST ADIPOSE DENSITY AND METABOLIC TUMOR CHARACTERISTICS COMPARED TO OTHER INDEXES
12. Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis
13. AXICABTAGENE CILOLEUCEL AS SECOND‐LINE THERAPY FOR LARGE B‐CELL LYMPHOMA IN TRANSPLANT‐INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
14. VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
15. FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study
16. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
17. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial
18. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
19. Corrigendum to “Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
20. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
21. Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen
22. EE138 Healthcare Resource Use (HCRU) and Associated Costs Among Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CAR-T Cells in France – A Real-World Study Using Data From PMSI
23. EPH145 Treatment Patterns Among Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Ineligible for Transplantation – A Real-World Study Using French PMSI
24. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
25. 805MO Real-world efficacy and safety of tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French DESCAR-T registry.
26. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
27. Supplement to: Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma.
28. Targeting of B‐cell receptor signalling in B‐cell malignancies
29. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party
30. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
31. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
32. Zanubrutinib in older patients (pts) with relapsed/refractory (r/r) marginal zone lymphoma (mzl): subgroup analysis of the magnolia study.
33. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
34. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
35. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study
36. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
37. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
38. Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
39. S210: CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN B-CELL NON-HODGKIN LYMPHOMA: REAL-WORLD STUDY FROM THE DESCAR-T REGISTRY
40. P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
41. S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY
42. P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
43. P1217: INTRATHECAL METHOTREXATE PROPHYLAXIS AND CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH INTENSIFIED R-ACVBP STRATEGY
44. PB2073: LACK OF AGREEMENT ON EVENT-FREE SURVIVAL DEFINITION IN MARGINAL ZONE LYMPHOMA
45. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
46. Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
47. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
48. GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF-κB-dependent induction of HIF-1α
49. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up
50. Hypometabolism on brain FDG-PET as a marker for neurotoxicity after CAR T-cell therapy: A case report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.